Who can see your viewing activity?
For Dr. Boggan can you discuss the importance of generalizability from this one focused study? What could be done "next" in terms of moving from "proof of concept" to a larger scale set of interventions to reduce ADEs?
One of the inherent challenges in writing an article like this is that the academic review would be on software from a different generation than the new test software. 7-11 years difference is like a software millennia. How would you suggest compensating for this challenge?
Here's a good reference to the most current activity at the Federal level re work on CDS. https://cds.ahrq.gov/
This is a great book if you want to read more on AI & Machine Learning in terms of fundamentals: https://www.amazon.com/Master-Algorithm-Ultimate-Learning-Machine/dp/1501299387 A bit older, but certainly not out of date...…..A great book!
FDA also getting into the business of regulating CDS in terms of the need to demonstrate efficacy and safety.....https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-decision-support-software
Also a book chapter I authored last year
Good also to target overuse of labs, Lauren https://www.choosingwisely.org/societies/american-society-for-clinical-pathology/
If you were to give these authors a grade for how well it followed SQUIRE guidelines, how would you guage it?
Nice job! Thanks, Dr. Boggan!
Looking forward to joining in the next Journal Club gathering!
Thank you to all!
thank you for putting together as well, looking forward to continuing to participate
Thanks to all contributors!